Targeting cancer-derived adenosine: new therapeutic approaches

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• CD73 generates immunosuppressive adenosine in the tumor microenvironment, promoting cancer progression and metastasis.
• Adenosine dysregulates immune cell infiltrates, leading to poor disease outcomes.
• Current therapies targeting the adenosinergic pathway show promise but require further development.

Purpose of the Study:

• To compare the merits and challenges of targeting CD73, CD39, and adenosine A(2A) receptors in cancer therapy.
• To identify potential tumor indications and combination strategies for adenosinergic pathway-targeted treatments.
• To review the current landscape of adenosinergic pathway inhibitors in oncology.

Main Methods:

• Literature review of current therapeutic approaches targeting the adenosinergic pathway.
• Comparison of efficacy and development status of CD73/CD39 antibodies and adenosine receptor antagonists.
• Analysis of preclinical and clinical data for adenosinergic pathway inhibitors in cancer.

Main Results:

• Antibodies targeting CD73 and CD39 demonstrate efficacy in preclinical cancer models.
• Humanized versions of CD73/CD39 antibodies are in early development.
• Adenosine A(2A) receptor antagonists are in late-stage clinical trials for Parkinson disease, with limited oncology data.
• High adenosine concentrations are found in various cancers, implicating it in tumor growth.

Conclusions:

• Targeting the adenosinergic pathway holds significant potential for cancer treatment.
• Combination strategies and specific tumor subtypes may benefit most from these therapies.
• Further clinical development is needed for humanized CD73/CD39 antibodies and adenosine receptor antagonists in oncology.